Santoni, M., Roviello, G., Grande, E., Giorgi, U. D., Fiala, O., Seront, E., . . . Massari, F. Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: A retrospective real-world comparison (ARON-1). Springer.
Chicago Style (17th ed.) CitationSantoni, Matteo, et al. Pembrolizumab-axitinib Versus Nivolumab-cabozantinib as First-line Therapy in Patients with Metastatic Renal Cell Carcinoma: A Retrospective Real-world Comparison (ARON-1). Springer.
MLA (9th ed.) CitationSantoni, Matteo, et al. Pembrolizumab-axitinib Versus Nivolumab-cabozantinib as First-line Therapy in Patients with Metastatic Renal Cell Carcinoma: A Retrospective Real-world Comparison (ARON-1). Springer.
Warning: These citations may not always be 100% accurate.